Frontiers in Oncology (Sep 2022)

ERBB2 promoter demethylation and immune cell infiltration promote a poor prognosis for cancer patients

  • Hongting Wang,
  • Hongting Wang,
  • Hongting Wang,
  • Hongting Wang,
  • Yongxu Jiang,
  • Huanhuan Jin,
  • Huanhuan Jin,
  • Huanhuan Jin,
  • Cunqin Wang,
  • Cunqin Wang,
  • Cunqin Wang

DOI
https://doi.org/10.3389/fonc.2022.1012138
Journal volume & issue
Vol. 12

Abstract

Read online

BackgroundReceptor tyrosine-protein kinase erbB-2 (ERBB2) expression is a critical factor for the prognosis of various cancers. ERBB2 enrichment indicates a poor prognosis in some cancer types but could be a favorable prognostic factor in others.MethodsWe analyzed DNA methylation, mRNA, protein, immune cell infiltration, and related signaling pathways using TIMER2.0, GEPIA2, STRING, and UALCAN portal datasets in tumor tissues of diverse cancer types and their matched normal tissues.ResultsERBB2 promoter demethylation increases transcript protein amplification and promotes a poor prognosis for cancer patients. ERBB2 gain-of-function procures immune cell infiltration for tumor growth and drives away T regulatory cells, which suppress or downregulate induction and proliferation of effector T cells. The downstream signaling pathways, such as tumor proliferation, ECM-related genes, and degradation of ECM, are involved in ERBB2 gene demethylation and immune activation in cancer progression.ConclusionERBB2 gene demethylation leads to a poor prognosis in cancer patients, which is strongly influenced by the composition and abundance of tumor immune cell infiltration. ERBB2 demethylation could be used in clinical practice to identify immune profiles and direct therapeutic strategies.

Keywords